Oncology Multiple Articles & Analysis
17 news found
The addition of these new applications will help us gain a better understanding of what drives cancers down to a molecular level,” said Thomas Stricker, MD, PhD, Pathology Lab Director, Center for Molecular and Genomic Studies, Tennessee Oncology. The laboratory at Tennessee Oncology will streamline multiple NGS tests within one end-to-end ...
“Antengene believes that cancer treatments involving the rational combination of immuno-oncology drugs and targeted therapies may offer the greatest opportunity for substantial advances in treatment outcomes for patients with cancer,” said Dr. ...
(Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following: As previously disclosed, clinical trial contracts and budgets have been executed at multiple hospitals and the ...
(Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ...
“We look forward to exploring CX-904 in solid tumors,” said Meredith Pelster, M.D., MSCI, a study investigator at Sarah Cannon Research Institute at Tennessee Oncology. “Given that EGFR is widely expressed in a number of solid tumors, the opportunity for this therapeutic candidate to address an unmet need in multiple tumor types is ...
“We have made tremendous progress over the last year in advancing multiple oncology programs toward the clinic. Looking forward, as we aim to transition from a platform company to a clinical-stage biotech, we are honored to welcome such a highly-successful drug developer to our leadership team—Kanya is uniquely suited to help Senti Bio navigate this ...
Its artificial intelligence and machine-learning based discovery engine is targeting bacteria across therapeutic areas including infectious disease, immunology, and oncology. Multiple non-dilutive strategic partnerships validate the company’s platform and programs. ...
(Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022. ...
(Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Frederick W. Gluck is retiring from its board of directors, effective June 30th, 2022. ...
(Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a virtual panel discussion at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 12:50 p.m. ...
Proceeds will be used to commercialize GeneCentric’s gene signatures and accelerate the growth of its pipeline of predictive response signatures for oncology therapeutics. New investors include IAG Capital Partners and Alexandria Venture Investments, along with existing investors Labcorp and Hatteras Venture Partners. ...
Its artificial intelligence and machine-learning based discovery engine is targeting bacteria across therapeutic areas including infectious disease, immunology, and oncology. Multiple non-dilutive strategic partnerships validate the company’s platform and programs. ...
Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform Adaptimmune will receive $150 million upfront, $150 million over the next five years in additional payments, ...
Exscientia has two active collaborations with Bristol Myers Squibb, which together focus on multiple therapeutic areas, including oncology and immunology. A significant expansion of the relationship was announced earlier this year. ...
Atomwise performed AI-based molecular screening using their proprietary AI technology, AtomNet, to generate compound hits with predicted activity against multiple mutant forms of the oncology targets for Hansoh. With AtomNet, the collaboration was able to screen an ultra-large and diverse virtual library of over 12 billion compounds, finding 200 predicted ...
PlasmaJet has been used in thousands of procedures in the United States and Europe in multiple specialties including oncologic, general and colorectal, plastic, and gynecological ...
An industry sales executive with 20 years of proven success, Gulick will continue to grow the current sales trajectory of the Company’s PlasmaJet system, positioning the product as a unique and versatile surgical technology suitable for multiple specialties. With PlasmaJet, the Company is pioneering a multi-dimensional technology platform that allows surgeons to treat ...